Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (COSM) reported record revenue of $53.6 million for the first nine months of 2026. Revenue rose 17.6% year over year, but the nine-month net loss widened to $14.15 million from $9.00 million. Q3 revenue fell to $16.68 million from $17.11 million a year earlier. Q3 gross margin rose 465 basis points from Q2 to 12.6%, and Q3 net loss narrowed to $5.25 million from $5.35 million a year earlier.
Since year-end 2025, total debt fell 33.8% to $12.83 million and stockholders’ equity rose 21.2% to $22.33 million. Cosmos Health fully settled its $8.0 million ATW convertible note. Cana Laboratories’ contract manufacturing pipeline rose 31% since June to more than 32.7 million units. Cosmos Health completed a 1-for-20 reverse stock split effective November 13, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point$8.0 million ATW convertible note was fully settled with accrued interest approximately twelve months before its August 2027 maturity 56% of market cap
- Moderate pointNine-month revenue reached a record $53.59 million, up 17.6% from $45.57 million a year earlier
- Moderate pointStockholders’ equity rose 21.2% to $22.33 million at September 30 from $18.42 million at year-end 2025
- Moderate pointQ3 gross margin rose 465 basis points to 12.6% from 7.96% in Q2
- Moderate pointU.S. monthly subscription value reached $1.83 million as of October 31, approximately $22 million annualized
- Moderate pointU.S. e-commerce sales reached $1.67 million in October
- Moderate pointCana Laboratories’ manufacturing pipeline grew 31% since June to more than 32.7 million units under agreements extending up to ten years
- Moderate pointCosmoFarm’s annualized revenue run rate exceeded $60 million based on Q2 revenue, approximately 4.3 times its revenue before Cosmos Health ownership
- Moderate pointShare repurchases totaled 123,100 shares in Q3 for approximately $0.63 million 4.4% of market cap
- Moderate pointAmazon UK sales rose 90% to $2.27 million over the trailing twelve months
23 minor points
- Minor pointTotal debt fell 33.8% to $12.83 million at September 30 from $19.37 million at year-end 2025
- Minor pointQ3 net loss narrowed to $5.25 million from $5.35 million a year earlier
- Minor pointWorking capital rose to $2.34 million at September 30 from $0.12 million at year-end 2025
- Minor pointTotal liabilities fell 18.2% to $38.49 million at September 30 from $47.05 million at year-end 2025
- Minor pointConvertible notes fell 81% to $1.22 million since year-end 2025
- Minor pointRelated derivative liability of $1.29 million was eliminated
- Minor pointDebt-to-equity ratio fell to 0.57 times at September 30 from 1.05 times at year-end 2025
- Minor pointLiabilities-to-equity ratio fell to 1.7 times at September 30 from 2.6 times at year-end 2025
- Minor pointLiabilities-to-assets ratio fell to 63.3% at September 30 from 71.9% at year-end 2025
- Minor pointQ3 interest expense fell 56.9% to $0.29 million from $0.67 million a year earlier
- Minor pointQ3 salaries and wages fell 10.5% year over year
- Minor pointU.S. direct-to-consumer subscriptions exceeded 12,500 active subscriptions as of October 31, 2026
- Minor point. Forward-looking: it has not happened yet and may not happen.Cana’s manufacturing pipeline represents over $20 million in implied revenue and over $18 million in implied gross profit
- Minor pointTarget Pharma agreements cover approximately 5.2 million units across two five-year manufacturing deals
- Minor pointViofar agreement covers an additional 2.5 million manufacturing units over five years
- Minor pointSaudi distribution agreement gives Innova Healthcare five years of exclusivity, with an initial order for 126,000 Sky Premium Life units
- Minor point. Forward-looking: it has not happened yet and may not happen.Saudi distribution volumes are expected to exceed 5 million units over the initial agreement term
- Minor pointCosmoFarm’s pharmacy customer base added more than 75 pharmacies during the first nine months of 2026
- Minor point. Forward-looking: it has not happened yet and may not happen.CosmoFarm automation entered commissioning and could support over $120 million in annual revenue
- Minor pointOceania e-commerce expansion reached Australia and New Zealand, with sales underway
- Minor point. Forward-looking: it has not happened yet and may not happen.Pharma Cell partnership expansion in Albania is projected to generate annualized orders exceeding 54,000 units
- Minor pointC-ScrubVet launched in the United Kingdom after successful testing and received its first orders
- Minor point. Forward-looking: it has not happened yet and may not happen.CCX0722 hydrogel intellectual property is planned for tokenization under a structure Cosmos Health describes as non-dilutive
Negative
- Major pointNine-month net loss widened to $14.15 million from $9.00 million a year earlier
- Moderate pointNine-month operating loss widened to $7,683,275 from $5,297,179 a year earlier
- Moderate pointNine-month gross profit fell to $4,996,836 from $5,816,231 a year earlier
- Moderate pointQ3 operating loss widened to $2,573,489 from $1,818,715 a year earlier
- Moderate pointNine-month adjusted EBITDA loss widened to $2,506,064 from $1,107,720 a year earlier
5 minor points
- Minor pointNine-month operating expenses rose 14.1% year over year, below revenue growth of 17.6%
- Minor pointQ3 revenue fell to $16.68 million from $17.11 million a year earlier, partly due to revenue reversals
- Minor pointQ3 gross profit fell to $2,104,003 from $2,602,618 a year earlier
- Minor pointQ3 operating expenses rose to $4,677,492 from $4,421,333 a year earlier
- Minor pointQ3 adjusted EBITDA loss, a non-GAAP earnings measure, narrowed approximately 18% from Q2 to $0.93 million but widened from $185,014 a year earlier
News Explained
By
Key Figures
- Nine-month revenue
- $53.59 million, up 17.6%
- Nine months ended September 30, 2026, versus 2025
- Q3 revenue
- $16.68 million
- Q3 2026; broadly in line with $17.11 million in Q3 2025
- Gross margin
- 12.6%, up 465 basis points
- Q3 2026 versus Q2 2026
- Adjusted EBITDA
- Loss of $0.93 million
- Q3 2026; improved approximately 18% sequentially from a loss of $1.13 million
- Total debt
- $12.83 million, down 33.8%
- As of September 30, 2026, compared with year-end 2025
- Stockholders' equity
- $22.33 million, up 21.2%
- As of September 30, 2026, compared with year-end 2025
- Active subscriptions
- More than 12,500
- U.S. direct-to-consumer business as of October 31, 2026
- Monthly subscription value
- $1.83 million
- U.S. direct-to-consumer business as of October 31, 2026
Previous Earnings Reports
-
Preliminary nine-month revenue rose 19%; the reported period’s price reaction was positive.
-
Reported record Q3 revenue, gross profit and margin; the reported period’s price reaction was negative.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
convertible notes financial
derivative liability financial
non-gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, IL / ACCESS Newswire / November 18, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM),a diversified, vertically integrated global healthcare group, today reported financial results for the third quarter and nine months ended September 30, 2026, highlighted by record nine-month revenue, a strengthened balance sheet and a sequential improvement in gross margin and Adjusted EBITDA.

Third Quarter and Nine-Month 2026 Financial Highlights
Revenue
- Nine-month revenue reached a record
$53.59 million , up$8.03 million , or17.6% , from$45.57 million in the first nine months of 2025, driven by strong momentum across core operating segments, including pharmaceutical distribution at CosmoFarm, which added more than 75 new pharmacies to its client portfolio during the period. - Third-quarter revenue was
$16.68 million , broadly in line with$17.11 million in the third quarter of 2025, and was partially impacted by revenue reversals.
Sequential Improvement in Gross Margin and Adjusted EBITDA
- Gross margin rebounded to
12.6% in Q3 2026, up 465 basis points from7.96% in Q2 2026. - Adjusted EBITDA improved approximately
18% sequentially, to a loss of$0.93 million from a loss of$1.13 million in Q2 2026.
Operating Discipline
- Nine-month total operating expenses grew
14.1% , below revenue growth of17.6% . - Third-quarter salaries and wages declined
10.5% year-over-year, while the Company increased sales and marketing investment to support its brands.
Lower Interest Expense
- Third-quarter interest expense fell
56.9% to$0.29 million , from$0.67 million in Q3 2025, as the Company reduced its debt during 2026.
Net Loss Driven by Non-Cash Charges
- Third-quarter net loss narrowed to
$5.25 million , from$5.35 million in Q3 2025. - Approximately
$3.1 million , or59% , of the Q3 net loss consisted of net non-cash charges related primarily to the Company's convertible notes, including non-cash interest expense and changes in fair value.
Balance Sheet Transformation
Cosmos Health continued to strengthen its capital structure in the third quarter, reducing total debt and total liabilities and increasing stockholders' equity in every quarter of 2026, while substantially improving working capital.
(in $ millions) | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 | Change YTD | |||||||||||||||
Total debt | 19.37 | 17.81 | 15.82 | 12.83 | -33.8 | % | ||||||||||||||
Total liabilities | 47.05 | 42.54 | 40.79 | 38.49 | -18.2 | % | ||||||||||||||
Stockholders' equity | 18.42 | 19.83 | 20.67 | 22.33 | +21.2 | % | ||||||||||||||
Total debt-to-equity | 1.05 | x | 0.90 | x | 0.77 | x | 0.57 | x | -45 | % | ||||||||||
Total liabilities-to-equity | 2.6 | x | 2.1 | x | 2.0 | x | 1.7 | x | -33 | % | ||||||||||
- Total assets were
$60.82 million as of September 30, 2026. The asset base remains diversified, including a solid real estate and intellectual property portfolio. - Total liabilities decreased
18.2% , or$8.56 million , to$38.49 million from$47.05 million at year-end 2025, driven primarily by a33.8% reduction in total debt to$12.83 million , which mainly reflected the full settlement of the$8.0 million ATW convertible note. Convertible notes fell81% to$1.22 million , and the related$1.29 million derivative liability was eliminated. - Total stockholders' equity increased by
$3.90 million , or21.2% , to$22.33 million from$18.42 million at December 31, 2025, while the liabilities-to-assets ratio improved by approximately 860 basis points to63.3% from71.9% . - Working capital improved to
$2.34 million , from$0.12 million at December 31, 2025.
Q3 2026 Business Highlights
U.S. Direct-to-Consumer
- Launched the Company's U.S. subscription model in July 2026 and introduced an AI-enabled subscription platform across B2C and B2B channels.
- Began scaling the U.S. direct-to-consumer business in mid-September 2026.
Commercial Expansion
- CosmoFarm reached an annualized revenue run-rate of over
$60 million , based on its record second-quarter 2026 revenue, approximately 4.3 times its revenue before Cosmos Health ownership, serving approximately 360 pharmacies daily within a network of more than 1,500. - Entered Saudi Arabia through an exclusive five-year distribution agreement with Innova Healthcare, with an initial purchase order of 126,000 Sky Premium Life® units and more than 5 million units expected over the initial term.
- Expanded the Pharma Cell partnership in Albania, with annualized orders projected to exceed 54,000 units.
- Signed an agreement with Libytec to commercialize DIABIT-IS X in Greece.
Contract Manufacturing: Record Pipeline
- Cana Laboratories grew its contract manufacturing pipeline to a record of more than 32.7 million units across 11 therapeutic categories, up
31% since June 2026, under agreements extending up to ten years, representing over$20 million in implied revenue and over$18 million in implied gross profit, including: - Two five-year agreements with Target Pharma for approximately 5.2 million units of MUPIROCIN and TRETIN.
- A five-year agreement with Viofar for an additional 2.5 million units.
Clinical Validation and New Categories
- Launched C-ScrubVet in the United Kingdom, entering the
$69 billion global animal health market following successful testing under EN 1656 and EN 1657, with first orders received.
R&D and Innovation
- Announced plans to tokenize the CCX0722 hydrogel intellectual property in a non-dilutive structure, targeting the
$562 billion weight-management market.
Capital Structure
- Fully settled the
$8.0 million ATW senior secured convertible note, including accrued interest, approximately twelve months ahead of its August 2027 maturity; no amounts remain outstanding under that note. - Repurchased 123,100 shares (2,462,000 pre-split) during the third quarter for approximately
$0.63 million , bringing total repurchases under the Company's$5.0 million share repurchase program to 255,600 shares (5,112,000 pre-split) for approximately$1.15 million .
Subsequent to Quarter-End
- U.S. direct-to-consumer business reached more than 12,500 active subscriptions and
$1.83 million in monthly subscription value as of October 31, 2026, approximately$22 million annualized, with October U.S. e-commerce sales of$1.67 million . - Expanded the e-commerce and subscription business to Australia, New Zealand and the broader Oceania region, with sales underway.
- Brands now sold in more than 40 countries across Europe, the Middle East, North America and Asia.
- Amazon UK sales grew
90% to$2.27 million over the trailing twelve months. - CosmoFarm began commissioning new automated order-processing and vehicle-loading infrastructure, building capacity that could support over
$120 million in annual revenue. - Effected a 1-for-20 reverse stock split of its common stock, effective November 13, 2026.
- Noble Capital Markets initiated equity research coverage of Cosmos Health with an Outperform rating.
Share Repurchase Program
On June 26, 2026, the Company's Board of Directors authorized the repurchase of up to
The Company may make further open-market repurchases from time to time, in accordance with applicable securities laws. The timing and amount of any repurchases will depend on market conditions and other factors, and the program may be suspended or discontinued at any time.
The Company will continue to evaluate capital allocation priorities, balancing strategic growth investments, liquidity requirements, debt reduction and potential share repurchases in accordance with market conditions and the Company's financial position.
CEO Commentary
Greg Siokas, CEO of Cosmos Health, stated: "We are pleased with our progress this year. We delivered record nine-month revenue of
"The third quarter also showed sequential improvement: gross margin rebounded by 465 basis points from the second quarter, Adjusted EBITDA improved by approximately
"What excites me most is what we are building in the United States. In roughly six weeks of scaling, our direct-to-consumer business grew to more than 12,500 active subscriptions and
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
| Three Months Ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
(in $) GAAP FIGURES | ||||||||||||||||
REVENUE | 16,679,476 | 17,110,425 | 53,593,744 | 45,568,655 | ||||||||||||
GROSS PROFIT | 2,104,003 | 2,602,618 | 4,996,836 | 5,816,231 | ||||||||||||
TOTAL OPERATING EXPENSES | 4,677,492 | 4,421,333 | 12,680,111 | 11,113,410 | ||||||||||||
GAIN (LOSS) FROM OPERATIONS | -2,573,489 | -1,818,715 | -7,683,275 | -5,297,179 | ||||||||||||
NET LOSS | -5,253,880 | -5,352,890 | -14,145,825 | -8,999,055 | ||||||||||||
NON-GAAP FIGURES | ||||||||||||||||
ADJUSTED REVENUE | 16,705,469 | 17,110,425 | 54,422,265 | 45,568,655 | ||||||||||||
ADJUSTED GROSS PROFIT | 2,129,996 | 2,602,618 | 5,825,357 | 5,816,231 | ||||||||||||
ADJUSTED EBITDA | -931,591 | -185,014 | -2,506,064 | -1,107,720 | ||||||||||||
ADJUSTED NET INCOME (LOSS) | -1,219,713 | -854,164 | -3,819,779 | -2,352,791 | ||||||||||||
(*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release.
Definitions of Non-GAAP Measures
We collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Gross Profit, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: Adjusted Revenue, Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Therefore, these non-GAAP financial measures are presented here. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP.
Adjusted Revenue
We define Adjusted Revenue as GAAP Revenue adjusted to include revenues subject to revenue recognition timing adjustments. Adjusted Revenue is supplemental in nature and is not meant as a substitute for Revenue prepared in accordance with GAAP.
Adjusted Gross Profit
We define Adjusted Gross Profit as GAAP Gross Profit adjusted for the same revenue recognition timing adjustments described under Adjusted Revenue above. Adjusted Gross Profit is supplemental in nature and is not meant as a substitute for Gross Profit prepared in accordance with GAAP.
Adjusted EBITDA
We define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), net, (iii) non-cash interest expense and change in fair value of convertible notes, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items, (vi) other income (expense), net, (vii) gain (loss) on equity investments, net, (viii) change in fair value of derivative liability, (ix) gain (loss) on digital assets, (x) foreign currency transaction, net, and (xi) sales discount reversals.
We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items.
For investors to better evaluate the Company's performance and compare results across reporting periods, Cosmos Health provides a reconciliation of GAAP to non-GAAP financial measures. These adjustments exclude certain non-cash and non-recurring items, including stock-based compensation, non-cash interest expense, changes in the fair value of derivatives and convertible notes, gains or losses on digital assets, foreign currency transactions, sales discount reversals, and other non-operating or non-recurring items, as applicable and as further described above.
The presentation of the Company's non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP, and the Company's non-GAAP measures may be different from non-GAAP measures used by other companies. Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.
Adjusted Net Income (Loss)
We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense.
Adjusted Net Income (Loss) has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.
Reconciliation of Non-GAAP Measures
Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA & Adjusted Net Income (Loss)
The following table presents reconciliations of Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA and Adjusted Net Income (Loss) to the most directly comparable GAAP financial measures for each of the periods indicated.
| Three Months Ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
(in $) | ||||||||||||||||
REVENUE | 16,679,476 | 17,110,425 | 53,593,744 | 45,568,655 | ||||||||||||
Sales discount reversal | 25,993 | - | 828,521 | - | ||||||||||||
ADJUSTED REVENUE | 16,705,469 | 17,110,425 | 54,422,265 | 45,568,655 | ||||||||||||
GROSS PROFIT | 2,104,003 | 2,602,618 | 4,996,836 | 5,816,231 | ||||||||||||
Sales discount reversal | 25,993 | - | 828,521 | - | ||||||||||||
ADJUSTED GROSS PROFIT | 2,129,996 | 2,602,618 | 5,825,357 | 5,816,231 | ||||||||||||
INCOME (LOSS) BEFORE INCOME TAXES | -5,253,880 | -5,352,890 | -14,145,825 | -8,999,055 | ||||||||||||
Adjustments (add back): | ||||||||||||||||
Depreciation and amortization expense | 343,087 | 377,911 | 1,040,447 | 1,052,212 | ||||||||||||
Interest (income) / expense, net | 288,122 | 669,150 | 1,313,715 | 1,245,071 | ||||||||||||
Non-cash interest expense | 2,940,463 | 201,447 | 3,732,226 | 364,550 | ||||||||||||
EBITDA | -1,682,208 | -4,104,382 | -8,059,437 | -6,337,222 | ||||||||||||
Sales discount reversal | 25,993 | - | 828,521 | - | ||||||||||||
Non-recurring and extraordinary items | 367,743 | 584,490 | 1,216,111 | 1,109,203 | ||||||||||||
Stock based compensation | 862,220 | 570,602 | 1,956,864 | 1,730,233 | ||||||||||||
Other (income) / expense, net | 115,324 | 5,577 | -363,717 | 115,904 | ||||||||||||
(Gain) / loss on equity investments, net | -5,377 | -2,998 | 2,225 | -8,779 | ||||||||||||
Non-cash interest expense / Change in fair value of convertible notes | 657,563 | 2,178,039 | 2,802,457 | 2,317,631 | ||||||||||||
Change in fair value of derivative liability | -482,883 | 311,778 | -1,292,198 | 311,778 | ||||||||||||
Gain/(Loss) on digital assets | -783,018 | -57 | 63,566 | -57 | ||||||||||||
Foreign currency transaction, net | -6,949 | 271,937 | 339,544 | -346,411 | ||||||||||||
ADJUSTED EBITDA | -931,591 | -185,014 | -2,506,064 | -1,107,720 | ||||||||||||
Interest income / (expense), net | -288,122 | -669,150 | -1,313,715 | -1,245,071 | ||||||||||||
ADJUSTED NET INCOME | -1,219,713 | -854,164 | -3,819,779 | -2,352,791 | ||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEET DATA
September 30, 2026 | June 30, 2026 | March 31, 2026 | ||||||||||
(in $) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||
ASSETS | ||||||||||||
Cash & cash equivalents | 1,091,385 | 2,445,168 | 2,158,921 | |||||||||
Inventory | 7,192,533 | 4,518,560 | 5,650,458 | |||||||||
Accounts receivable, prepaid expenses and other current assets | 28,455,111 | 29,217,388 | 28,594,752 | |||||||||
Property and equipment, net | 10,034,117 | 10,140,150 | 10,280,203 | |||||||||
Goodwill and intangible assets, net | 6,736,815 | 6,965,934 | 7,225,011 | |||||||||
Loans receivable | 3,371,528 | 3,472,916 | 3,605,388 | |||||||||
Other noncurrent assets | 3,934,685 | 4,701,838 | 4,854,278 | |||||||||
TOTAL ASSETS | 60,816,174 | 61,461,954 | 62,369,011 | |||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||
Accounts payable and accrued expenses | 16,167,249 | 15,297,625 | 15,689,061 | |||||||||
Other current liabilities | 7,103,687 | 6,760,621 | 6,701,051 | |||||||||
Lines of credit | 8,653,475 | 8,745,807 | 7,856,208 | |||||||||
Notes payable | 4,176,506 | 7,075,633 | 9,954,812 | |||||||||
Other non-current and finance/lease liabilities | 2,387,624 | 2,907,785 | 2,341,520 | |||||||||
Stockholders' and mezzanine equity | 22,327,633 | 20,674,484 | 19,826,359 | |||||||||
TOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY | 60,816,174 | 61,461,954 | 62,369,011 | |||||||||
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.